Device pulled from market due to inconsistent results.

This study is being conducted to study the use and application of a point-of-care (POC) Covid-19 test developed by Spartan BioSciences and recently approved for clinical use by Health Canada.

This RAPID COVID-19 study is a prospective, unblinded clinical trial. POC testing utilizing the Spartan Cube COVID-19 platform will be performed on a cohort of 2200 hospitalized patients who have been tested for COVID-19.

This cohort will be divided into three groups:

1. patients consulted upon by ICU, internal medicine, or cardiology for admission to the hospital
2. patients undergoing cardiac testing and/or procedures
3. patients awaiting surgery The results from the POC test will be compared to the results from the traditional hospital core lab test to determine sensitivity and specificity of the POC test.

An additional cohort of 500 quarantined health care workers will have the POC test performed and compared with the results from the traditional hospital core lab test.

Inclusion Criteria:

• participants >/= 18 years of age
• patients for whom POC testing would change their course of treatment (in opinion of treatment team)

Exclusion Criteria:

• patients in whom conventional COVID-19 testing would not have otherwise been performed
• patients in whom immediate COVID-19 testing would not alter short-term treatment
• patients who refuse consent